Anthem Biosciences Ltd. (ANTHEM.NS) Stock Competitors & Peer Comparison
See (ANTHEM.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ANTHEM.NS | ₹773.00 | -2.28% | 430.4B | 73.39 | ₹10.44 | N/A |
| BIOCON.BO | ₹422.50 | +1.64% | 575.9B | 148.89 | ₹2.83 | +0.12% |
| BIOCON.NS | ₹423.45 | +1.91% | 575.8B | 148.80 | ₹2.83 | +0.12% |
| ONESOURCE.NS | ₹1,561.50 | -2.93% | 185.1B | -251.14 | -₹6.43 | N/A |
| SYNGENE.NS | ₹435.85 | -1.11% | 178.1B | 56.20 | ₹7.89 | +0.28% |
| SYNGENE.BO | ₹435.65 | -1.19% | 178.1B | 56.49 | ₹7.85 | +0.28% |
| CONCORDBIO.BO | ₹1,318.30 | +0.13% | 140.2B | 54.14 | ₹24.75 | +0.80% |
| CONCORDBIO.NS | ₹1,321.00 | +0.45% | 139.9B | 54.11 | ₹24.72 | +0.80% |
| BLUEJET.BO | ₹514.15 | +0.29% | 90.5B | 36.45 | ₹14.30 | +0.23% |
| BLUEJET.NS | ₹515.00 | +0.47% | 90.5B | 36.47 | ₹14.30 | +0.23% |
Stock Comparison
ANTHEM.NS vs BIOCON.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, BIOCON.BO has a market cap of 575.9B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while BIOCON.BO trades at ₹422.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas BIOCON.BO's P/E ratio is 148.89. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to BIOCON.BO's ROE of +0.01%. Regarding short-term risk, ANTHEM.NS is more volatile compared to BIOCON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ANTHEM.NS.Check BIOCON.BO's competition here
ANTHEM.NS vs BIOCON.NS Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, BIOCON.NS has a market cap of 575.8B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while BIOCON.NS trades at ₹423.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas BIOCON.NS's P/E ratio is 148.80. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to BIOCON.NS's ROE of +0.01%. Regarding short-term risk, ANTHEM.NS is more volatile compared to BIOCON.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ANTHEM.NS.Check BIOCON.NS's competition here
ANTHEM.NS vs ONESOURCE.NS Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, ONESOURCE.NS has a market cap of 185.1B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while ONESOURCE.NS trades at ₹1,561.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas ONESOURCE.NS's P/E ratio is -251.14. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to ONESOURCE.NS's ROE of -0.01%. Regarding short-term risk, ANTHEM.NS is less volatile compared to ONESOURCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check ONESOURCE.NS's competition here
ANTHEM.NS vs SYNGENE.NS Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, SYNGENE.NS has a market cap of 178.1B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while SYNGENE.NS trades at ₹435.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas SYNGENE.NS's P/E ratio is 56.20. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to SYNGENE.NS's ROE of +0.07%. Regarding short-term risk, ANTHEM.NS is less volatile compared to SYNGENE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check SYNGENE.NS's competition here
ANTHEM.NS vs SYNGENE.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, SYNGENE.BO has a market cap of 178.1B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while SYNGENE.BO trades at ₹435.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas SYNGENE.BO's P/E ratio is 56.49. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to SYNGENE.BO's ROE of +0.07%. Regarding short-term risk, ANTHEM.NS is less volatile compared to SYNGENE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check SYNGENE.BO's competition here
ANTHEM.NS vs CONCORDBIO.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, CONCORDBIO.BO has a market cap of 140.2B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while CONCORDBIO.BO trades at ₹1,318.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas CONCORDBIO.BO's P/E ratio is 54.14. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to CONCORDBIO.BO's ROE of +0.14%. Regarding short-term risk, ANTHEM.NS is more volatile compared to CONCORDBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ANTHEM.NS.Check CONCORDBIO.BO's competition here
ANTHEM.NS vs CONCORDBIO.NS Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, CONCORDBIO.NS has a market cap of 139.9B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while CONCORDBIO.NS trades at ₹1,321.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas CONCORDBIO.NS's P/E ratio is 54.11. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to CONCORDBIO.NS's ROE of +0.14%. Regarding short-term risk, ANTHEM.NS is more volatile compared to CONCORDBIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ANTHEM.NS.Check CONCORDBIO.NS's competition here
ANTHEM.NS vs BLUEJET.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, BLUEJET.BO has a market cap of 90.5B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while BLUEJET.BO trades at ₹514.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas BLUEJET.BO's P/E ratio is 36.45. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to BLUEJET.BO's ROE of +0.20%. Regarding short-term risk, ANTHEM.NS is less volatile compared to BLUEJET.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check BLUEJET.BO's competition here
ANTHEM.NS vs BLUEJET.NS Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, BLUEJET.NS has a market cap of 90.5B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while BLUEJET.NS trades at ₹515.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas BLUEJET.NS's P/E ratio is 36.47. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to BLUEJET.NS's ROE of +0.20%. Regarding short-term risk, ANTHEM.NS is less volatile compared to BLUEJET.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check BLUEJET.NS's competition here
ANTHEM.NS vs SUPRIYA.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, SUPRIYA.BO has a market cap of 74.7B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while SUPRIYA.BO trades at ₹960.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas SUPRIYA.BO's P/E ratio is 35.68. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to SUPRIYA.BO's ROE of +0.20%. Regarding short-term risk, ANTHEM.NS is less volatile compared to SUPRIYA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check SUPRIYA.BO's competition here
ANTHEM.NS vs SUPRIYA.NS Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, SUPRIYA.NS has a market cap of 74.6B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while SUPRIYA.NS trades at ₹961.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas SUPRIYA.NS's P/E ratio is 35.66. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to SUPRIYA.NS's ROE of +0.20%. Regarding short-term risk, ANTHEM.NS is less volatile compared to SUPRIYA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check SUPRIYA.NS's competition here
ANTHEM.NS vs ZOTA.NS Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, ZOTA.NS has a market cap of 41.5B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while ZOTA.NS trades at ₹1,375.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas ZOTA.NS's P/E ratio is -60.89. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to ZOTA.NS's ROE of -0.21%. Regarding short-term risk, ANTHEM.NS is more volatile compared to ZOTA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ANTHEM.NS.Check ZOTA.NS's competition here
ANTHEM.NS vs PANACEABIO.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, PANACEABIO.BO has a market cap of 32.3B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while PANACEABIO.BO trades at ₹552.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas PANACEABIO.BO's P/E ratio is -596.31. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to PANACEABIO.BO's ROE of -0.01%. Regarding short-term risk, ANTHEM.NS is less volatile compared to PANACEABIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check PANACEABIO.BO's competition here
ANTHEM.NS vs PANACEABIO.NS Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, PANACEABIO.NS has a market cap of 32.1B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while PANACEABIO.NS trades at ₹551.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas PANACEABIO.NS's P/E ratio is -609.42. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to PANACEABIO.NS's ROE of -0.01%. Regarding short-term risk, ANTHEM.NS is less volatile compared to PANACEABIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check PANACEABIO.NS's competition here
ANTHEM.NS vs DCAL.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, DCAL.BO has a market cap of 27.2B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while DCAL.BO trades at ₹172.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas DCAL.BO's P/E ratio is 27.85. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to DCAL.BO's ROE of +0.02%. Regarding short-term risk, ANTHEM.NS is less volatile compared to DCAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check DCAL.BO's competition here
ANTHEM.NS vs DCAL.NS Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, DCAL.NS has a market cap of 27.1B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while DCAL.NS trades at ₹173.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas DCAL.NS's P/E ratio is 27.88. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to DCAL.NS's ROE of +0.02%. Regarding short-term risk, ANTHEM.NS is less volatile compared to DCAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check DCAL.NS's competition here
ANTHEM.NS vs TITANBIO.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, TITANBIO.BO has a market cap of 17.7B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while TITANBIO.BO trades at ₹417.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas TITANBIO.BO's P/E ratio is 59.52. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to TITANBIO.BO's ROE of +0.18%. Regarding short-term risk, ANTHEM.NS is less volatile compared to TITANBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check TITANBIO.BO's competition here
ANTHEM.NS vs 3BBLACKBIO.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, 3BBLACKBIO.BO has a market cap of 10.3B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while 3BBLACKBIO.BO trades at ₹1,189.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas 3BBLACKBIO.BO's P/E ratio is 17.15. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to 3BBLACKBIO.BO's ROE of +0.20%. Regarding short-term risk, ANTHEM.NS is less volatile compared to 3BBLACKBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check 3BBLACKBIO.BO's competition here
ANTHEM.NS vs FERMENTA.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, FERMENTA.BO has a market cap of 9.8B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while FERMENTA.BO trades at ₹353.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas FERMENTA.BO's P/E ratio is 13.94. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to FERMENTA.BO's ROE of +0.19%. Regarding short-term risk, ANTHEM.NS is less volatile compared to FERMENTA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check FERMENTA.BO's competition here
ANTHEM.NS vs KILPEST.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, KILPEST.BO has a market cap of 6.3B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while KILPEST.BO trades at ₹808.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas KILPEST.BO's P/E ratio is 18.32. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to KILPEST.BO's ROE of N/A. Regarding short-term risk, ANTHEM.NS is more volatile compared to KILPEST.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ANTHEM.NS.Check KILPEST.BO's competition here
ANTHEM.NS vs TAKE.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, TAKE.BO has a market cap of 4.4B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while TAKE.BO trades at ₹30.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas TAKE.BO's P/E ratio is 104.00. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to TAKE.BO's ROE of +0.44%. Regarding short-term risk, ANTHEM.NS is more volatile compared to TAKE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ANTHEM.NS.Check TAKE.BO's competition here
ANTHEM.NS vs TAKE.NS Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, TAKE.NS has a market cap of 4.4B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while TAKE.NS trades at ₹29.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas TAKE.NS's P/E ratio is 103.03. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to TAKE.NS's ROE of +0.44%. Regarding short-term risk, ANTHEM.NS is more volatile compared to TAKE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ANTHEM.NS.Check TAKE.NS's competition here
ANTHEM.NS vs HALEOSLABS.NS Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, HALEOSLABS.NS has a market cap of 4.3B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while HALEOSLABS.NS trades at ₹1,372.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas HALEOSLABS.NS's P/E ratio is 24.77. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to HALEOSLABS.NS's ROE of +0.09%. Regarding short-term risk, ANTHEM.NS is less volatile compared to HALEOSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check HALEOSLABS.NS's competition here
ANTHEM.NS vs HALEOSLABS.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, HALEOSLABS.BO has a market cap of 4.2B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while HALEOSLABS.BO trades at ₹1,310.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas HALEOSLABS.BO's P/E ratio is 24.21. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to HALEOSLABS.BO's ROE of +0.09%. Regarding short-term risk, ANTHEM.NS is less volatile compared to HALEOSLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check HALEOSLABS.BO's competition here
ANTHEM.NS vs SMSLIFE.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, SMSLIFE.BO has a market cap of 4.2B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while SMSLIFE.BO trades at ₹1,310.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas SMSLIFE.BO's P/E ratio is 22.39. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to SMSLIFE.BO's ROE of +0.08%. Regarding short-term risk, ANTHEM.NS is less volatile compared to SMSLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check SMSLIFE.BO's competition here
ANTHEM.NS vs SMSLIFE.NS Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, SMSLIFE.NS has a market cap of 3.9B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while SMSLIFE.NS trades at ₹1,299.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas SMSLIFE.NS's P/E ratio is 21.01. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to SMSLIFE.NS's ROE of +0.10%. Regarding short-term risk, ANTHEM.NS is more volatile compared to SMSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ANTHEM.NS.Check SMSLIFE.NS's competition here
ANTHEM.NS vs LYKALABS.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, LYKALABS.BO has a market cap of 2.4B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while LYKALABS.BO trades at ₹67.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas LYKALABS.BO's P/E ratio is 116.10. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to LYKALABS.BO's ROE of -0.10%. Regarding short-term risk, ANTHEM.NS is less volatile compared to LYKALABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check LYKALABS.BO's competition here
ANTHEM.NS vs LYKALABS.NS Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, LYKALABS.NS has a market cap of 2.4B. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while LYKALABS.NS trades at ₹66.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas LYKALABS.NS's P/E ratio is -24.30. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to LYKALABS.NS's ROE of -0.10%. Regarding short-term risk, ANTHEM.NS is less volatile compared to LYKALABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check LYKALABS.NS's competition here
ANTHEM.NS vs ALFAVIO.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, ALFAVIO.BO has a market cap of 269.9M. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while ALFAVIO.BO trades at ₹8.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas ALFAVIO.BO's P/E ratio is 214.00. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to ALFAVIO.BO's ROE of +0.00%. Regarding short-term risk, ANTHEM.NS is less volatile compared to ALFAVIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check ALFAVIO.BO's competition here
ANTHEM.NS vs TRABI.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, TRABI.BO has a market cap of 228.8M. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while TRABI.BO trades at ₹2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas TRABI.BO's P/E ratio is -13.73. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to TRABI.BO's ROE of -0.18%. Regarding short-term risk, ANTHEM.NS is less volatile compared to TRABI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check TRABI.BO's competition here
ANTHEM.NS vs VANTABIO.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, VANTABIO.BO has a market cap of 180.3M. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while VANTABIO.BO trades at ₹25.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas VANTABIO.BO's P/E ratio is 169.00. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to VANTABIO.BO's ROE of -0.17%. Regarding short-term risk, ANTHEM.NS is less volatile compared to VANTABIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check VANTABIO.BO's competition here
ANTHEM.NS vs SAMSRITA.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, SAMSRITA.BO has a market cap of 179M. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while SAMSRITA.BO trades at ₹11.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas SAMSRITA.BO's P/E ratio is -3.03. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to SAMSRITA.BO's ROE of -0.64%. Regarding short-term risk, ANTHEM.NS is less volatile compared to SAMSRITA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check SAMSRITA.BO's competition here
ANTHEM.NS vs STARSOURCE.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, STARSOURCE.BO has a market cap of 142M. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while STARSOURCE.BO trades at ₹98.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas STARSOURCE.BO's P/E ratio is -1.20. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to STARSOURCE.BO's ROE of -0.93%. Regarding short-term risk, ANTHEM.NS is less volatile compared to STARSOURCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check STARSOURCE.BO's competition here
ANTHEM.NS vs GVBL.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, GVBL.BO has a market cap of 102.1M. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while GVBL.BO trades at ₹35.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas GVBL.BO's P/E ratio is 334.40. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to GVBL.BO's ROE of -0.01%. Regarding short-term risk, ANTHEM.NS is more volatile compared to GVBL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ANTHEM.NS.Check GVBL.BO's competition here
ANTHEM.NS vs SERVOTEACH.BO Comparison June 2026
ANTHEM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANTHEM.NS stands at 430.4B. In comparison, SERVOTEACH.BO has a market cap of 0. Regarding current trading prices, ANTHEM.NS is priced at ₹773.00, while SERVOTEACH.BO trades at ₹20.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANTHEM.NS currently has a P/E ratio of 73.39, whereas SERVOTEACH.BO's P/E ratio is N/A. In terms of profitability, ANTHEM.NS's ROE is +0.22%, compared to SERVOTEACH.BO's ROE of +0.00%. Regarding short-term risk, ANTHEM.NS is less volatile compared to SERVOTEACH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ANTHEM.NS.Check SERVOTEACH.BO's competition here